277 related articles for article (PubMed ID: 35902484)
1. Autologous Hematopoietic Stem-Cell Transplantation in Multiple Sclerosis: A Systematic Review and Meta-Analysis.
Nabizadeh F; Pirahesh K; Rafiei N; Afrashteh F; Ahmadabad MA; Zabeti A; Mirmosayyeb O
Neurol Ther; 2022 Dec; 11(4):1553-1569. PubMed ID: 35902484
[TBL] [Abstract][Full Text] [Related]
2. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.
Muraro PA; Pasquini M; Atkins HL; Bowen JD; Farge D; Fassas A; Freedman MS; Georges GE; Gualandi F; Hamerschlak N; Havrdova E; Kimiskidis VK; Kozak T; Mancardi GL; Massacesi L; Moraes DA; Nash RA; Pavletic S; Ouyang J; Rovira M; Saiz A; Simoes B; Trnený M; Zhu L; Badoglio M; Zhong X; Sormani MP; Saccardi R;
JAMA Neurol; 2017 Apr; 74(4):459-469. PubMed ID: 28241268
[TBL] [Abstract][Full Text] [Related]
3. Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab.
Boffa G; Lapucci C; Sbragia E; Varaldo R; Raiola AM; Currò D; Roccatagliata L; Capello E; Laroni A; Mikulska M; Gualandi F; Uccelli A; Angelucci E; Mancardi GL; Inglese M
Eur J Neurol; 2020 Oct; 27(10):2047-2055. PubMed ID: 32418281
[TBL] [Abstract][Full Text] [Related]
4. Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline.
Bayas A; Berthele A; Blank N; Dreger P; Faissner S; Friese MA; Gerdes LA; Grauer OM; Häussler V; Heesen C; Janson D; Korporal-Kuhnke M; Kowarik M; Kröger N; Lünemann JD; Martin R; Meier U; Meuth S; Muraro P; Platten M; Schirmer L; Stürner KH; Stellmann JP; Scheid C; Bergh FT; Warnke C; Wildemann B; Ziemssen T
Ther Adv Neurol Disord; 2023; 16():17562864231180730. PubMed ID: 37780055
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: a systematic review and meta-analysis.
Ge F; Lin H; Li Z; Chang T
Neurol Sci; 2019 Mar; 40(3):479-487. PubMed ID: 30535563
[TBL] [Abstract][Full Text] [Related]
6. Benefits of aHSCT over alemtuzumab in patients with multiple sclerosis besides disability and relapses: Sustained improvement in cognition and quality of life.
Braun B; Fischbach F; Richter J; Pfeffer LK; Fay H; Reinhardt S; Friese MA; Stellmann JP; Kröger NM; Heesen C; Häußler V
Mult Scler Relat Disord; 2024 Feb; 82():105414. PubMed ID: 38176284
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of autografting persons with multiple sclerosis are better in those not exposed to prior disease-modifying therapies.
Sánchez-Bonilla D; Robles-Nasta M; Gallardo-Pérez MM; Hernández-Flores EJ; Montes-Robles M; Pastelín-Martínez ML; Garcés-Eisele SJ; Olivares-Gazca JC; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
Mult Scler Relat Disord; 2023 Jul; 75():104744. PubMed ID: 37178580
[TBL] [Abstract][Full Text] [Related]
8. Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis.
Mariottini A; Filippini S; Innocenti C; Forci B; Mechi C; Barilaro A; Fani A; Carlucci G; Saccardi R; Massacesi L; Repice AM
Mult Scler; 2021 Jan; 27(1):61-70. PubMed ID: 32008439
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives.
Shevchenko JL; Kuznetsov AN; Ionova TI; Melnichenko VY; Fedorenko DA; Kurbatova KA; Gorodokin GI; Novik AA
Ann Hematol; 2015 Jul; 94(7):1149-57. PubMed ID: 25711670
[TBL] [Abstract][Full Text] [Related]
10. Autologous hematopoietic stem cell transplantation of patients with aggressive relapsing-remitting multiple sclerosis: Danish nation-wide experience.
Jespersen F; Petersen SL; Andersen P; Sellebjerg F; Magyari M; Sørensen PS; Blinkenberg M
Mult Scler Relat Disord; 2023 Aug; 76():104829. PubMed ID: 37364374
[TBL] [Abstract][Full Text] [Related]
11. Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series.
Nicholas RS; Rhone EE; Mariottini A; Silber E; Malik O; Singh-Curry V; Turner B; Scalfari A; Ciccarelli O; Sormani MP; Olavarria E; Mehra V; Gabriel I; Kazmi MA; Muraro P;
Neurology; 2021 Aug; 97(9):e890-e901. PubMed ID: 34253634
[TBL] [Abstract][Full Text] [Related]
12. Autologous haematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis.
Mariottini A; Bulgarini G; Forci B; Innocenti C; Mealli F; Mattei A; Ceccarelli C; Repice AM; Barilaro A; Mechi C; Saccardi R; Massacesi L
Eur J Neurol; 2022 Jun; 29(6):1708-1718. PubMed ID: 35146841
[TBL] [Abstract][Full Text] [Related]
13. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
Moore JJ; Massey JC; Ford CD; Khoo ML; Zaunders JJ; Hendrawan K; Barnett Y; Barnett MH; Kyle KA; Zivadinov R; Ma KC; Milliken ST; Sutton IJ; Ma DDF
J Neurol Neurosurg Psychiatry; 2019 May; 90(5):514-521. PubMed ID: 30538138
[TBL] [Abstract][Full Text] [Related]
14. aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis.
Häußler V; Ufer F; Pöttgen J; Wolschke C; Friese MA; Kröger N; Heesen C; Stellmann JP
Ann Clin Transl Neurol; 2021 Jun; 8(6):1269-1278. PubMed ID: 33949790
[TBL] [Abstract][Full Text] [Related]
15. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS.
Saiz A; Carreras E; Berenguer J; Yagüe J; Martínez C; Marín P; Rovira M; Pujol T; Arbizu T; Graus F
Neurology; 2001 Apr; 56(8):1084-9. PubMed ID: 11320183
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis.
Nabizadeh F; Mohamadi M; Rahmani S; Rajabi R; Afrashteh F; Najdaghi S; Mirmosayyeb O
Neurol Sci; 2023 Sep; 44(9):3045-3057. PubMed ID: 37062787
[TBL] [Abstract][Full Text] [Related]
17. [Multiple sclerosis: interventions to halt disease : Which patients can be considered for autologous stem cell transplantation].
Willison AG; Meuth SG
Nervenarzt; 2022 Oct; 93(10):987-999. PubMed ID: 35951049
[TBL] [Abstract][Full Text] [Related]
18. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
Casanova B; Jarque I; Gascón F; Hernández-Boluda JC; Pérez-Miralles F; de la Rubia J; Alcalá C; Sanz J; Mallada J; Cervelló A; Navarré A; Carcelén-Gadea M; Boscá I; Gil-Perotin S; Solano C; Sanz MA; Coret F
Neurol Sci; 2017 Jul; 38(7):1213-1221. PubMed ID: 28396953
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of stem cell transplantation for multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials.
Nawar AA; Farid AM; Wally R; Tharwat EK; Sameh A; Elkaramany Y; Asla MM; Kamel WA
Sci Rep; 2024 May; 14(1):12545. PubMed ID: 38822024
[TBL] [Abstract][Full Text] [Related]
20. Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient.
Obradović D; Tukić L; Radovinović-Tasić S; Petrović B; Elez M; Ostojić G; Balint B
Vojnosanit Pregl; 2016 May; 73(5):504-8. PubMed ID: 27430119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]